NIVFNasdaqServices-Misc Health & Allied Services, NECAlso trades as NIVFW
NewGenIvf Group Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$0.28+0.00 (+1.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Gross margin
20.2%
Operating margin
-226.9%
Net margin
209.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -13.0% | -7.4% | – | – | |
| Gross profit | -47.7% | -14.7% | – | – | |
| Net income | – | +178.2% | – | – | |
| EPS, diluted | – | -13.6% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 77.2% | |
| Return on assets | – | – | 54.4% | |
| Current ratio | – | – | 3.12 | |
| Interest coverage | – | – | -17.4× | |
| Inventory turnover | – | – | 18.1× | |
| Capex to revenue | – | – | 2.9% | |
| Diluted shares | – | – | 3M |
Where the cash went
Fiscal 2021 to 2025, five years combined
NewGenIvf generated $24.10M from operations and spent $368.95K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$24.10M
Used
$368.95K
Capital expenditure$368.95K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin209.0%
×Asset turnover0.26×
×Equity multiplier1.42×
=Return on equity, FY202577.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 209.0% | 0.26× | 1.42× | 77.2% |
| FY2024 | -9.7% | 1.35× | 3.00× | -39.1% |
| FY2023 | 2.5% | 1.39× | 1.72× | 6.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$9.88M
- Cash generatingOperating cash flow above zero-$10.93M
- Return on assets improvedROA up on the prior year-11.7% → 276.1%
- Earnings backed by cashOperating cash flow above net income-$10.93M vs $9.88M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.17 → 3.12
- No dilutionShare count did not rise0M → 3M
- Gross margin improvedGross margin up on the prior year33.62% → 20.22%
- More efficientAsset turnover rose1.21 → 1.32